Connect with us

Health

When the Weight Comes Back: What Happens After You Stop Taking GLP-1 Drugs?

Published

on

Millions of Americans have turned to medications such as Wegovy and Zepbound to lose weight, often with results that once seemed difficult to achieve without surgery.

But what happens when someone stops taking the medication?

The answer goes beyond the bathroom scale.

Research shows that people who discontinue these treatments often regain a substantial portion of the weight they lost. At the same time, improvements in blood pressure, cholesterol, and blood sugar can begin moving back toward their previous levels.

The findings raise an important question for patients who cannot afford to continue treatment, experience troublesome side effects, or simply hope to stop taking medication once they reach their weight-loss goal.

Is weight-loss treatment something you finish, or something you may need to continue for years?

The Study That Followed Patients After They Stopped

Semaglutide, the active ingredient in Wegovy, received FDA approval for chronic weight management in June 2021.

Its approval followed clinical trials demonstrating significant weight loss among people taking the medication alongside lifestyle changes.

One of those studies, known as STEP 1, enrolled 1,961 adults with obesity or overweight and a weight-related health condition, but without diabetes.

Participants received either semaglutide or a placebo for 68 weeks, along with lifestyle counseling.

A smaller group of 327 participants was then followed for another year after the medication and structured lifestyle intervention ended.

The results were striking.

People who had taken semaglutide had lost an average of 17.3% of their starting body weight during treatment.

One year after stopping, they had regained an average of 11.6 percentage points.

That represented approximately two-thirds of the weight they had lost.

Consider someone who weighed 250 pounds before treatment.

A 17.3% reduction would bring that person’s weight to approximately 207 pounds.

Regaining 11.6% of the original weight would mean gaining back about 29 pounds, bringing the person to roughly 236 pounds.

These illustrations are based on study averages, not predictions for individual patients.

Although much of the weight returned, participants did not necessarily lose every benefit. On average, they remained 5.6% below their original body weight after a year without treatment.

Blood Pressure, Cholesterol, and Blood Sugar Also Changed

The weight regain attracted attention, but researchers discovered another important pattern.

During treatment, participants experienced improvements in several measures of metabolic and cardiovascular health.

Blood pressure decreased. Cholesterol levels improved. Blood sugar measurements moved in a healthier direction.

After the medication was discontinued, many of those improvements began to reverse.

By the end of the additional year, most measured cardiovascular and metabolic indicators had moved back toward pretreatment levels.

The findings were published in the journal Diabetes, Obesity and Metabolism in 2022.

Researchers concluded that the results support treating obesity as a chronic, relapsing medical condition rather than a temporary problem that medication can permanently resolve.

That distinction matters because the benefits of losing weight are not limited to appearance or clothing size.

Improved blood pressure, blood sugar, and cholesterol can help reduce long-term health risks.

However, the study did not establish that every health improvement disappears after treatment stops, nor did it measure whether discontinuation directly caused more heart attacks or strokes.

A Second Drug Shows a Similar Pattern

Researchers observed comparable results with tirzepatide, the medication used in Zepbound.

In the SURMOUNT-4 clinical trial, participants received tirzepatide for 36 weeks.

During that initial treatment period, they lost an average of 20.9% of their body weight.

The researchers then randomly assigned 670 participants to continue taking tirzepatide or switch to a placebo for another 52 weeks.

Those who continued treatment lost an additional 5.5% of their weight, on average.

Those switched to placebo regained approximately 14% of their body weight over the following year, measured from the point when they stopped the medication.

By the end of the study, 89.5% of participants who continued tirzepatide had maintained at least 80% of their initial weight loss.

Among those switched to placebo, only 16.6% maintained that much of their earlier progress.

The results, published in JAMA, reinforced an emerging conclusion: These medications can be highly effective while patients take them, but maintaining the results after stopping can be difficult.

Why Does the Weight Return?

It might be tempting to assume that people regain weight because they return to old habits.

But the biology is more complicated.

GLP-1 medications help regulate appetite, fullness, and food intake.

Semaglutide mimics the effects of a hormone called glucagon-like peptide-1. Tirzepatide acts on both GLP-1 and another hormone pathway known as GIP.

These medications help people feel satisfied after eating and reduce hunger and food cravings.

When treatment stops, those effects gradually wear off.

Appetite may return, sometimes making it much more difficult to maintain the same food intake that supported weight loss.

The body also adapts to a smaller size.

A person who weighs substantially less generally needs fewer calories to maintain that lower weight. Biological responses to weight loss can also favor regaining weight.

That creates a difficult combination: Hunger may increase just as the body requires less energy than it did before.

This is one reason researchers increasingly describe obesity as a chronic condition involving complex biological mechanisms, rather than simply a matter of willpower.

Many Patients Stop Within the First Year

Clinical trials demonstrate what happens under carefully controlled conditions.

Real-world treatment presents another challenge: Many patients do not remain on GLP-1 medications long enough to receive sustained benefits.

A study published in JAMA Network Open in January 2025 examined health records from 125,474 adults who began taking GLP-1 medications.

Among patients without Type 2 diabetes, 64.8% discontinued treatment within one year.

Even among patients with Type 2 diabetes, 46.5% stopped within that period.

Researchers found that income, side effects, and weight-loss outcomes were associated with treatment discontinuation.

Other studies have identified medication cost, insurance coverage, drug shortages, and difficulties tolerating treatment as potential barriers.

For some people, stopping is a personal decision.

For others, continuing simply isn’t financially or medically practical.

When treatment ends, the biological effects that helped control appetite and weight begin to fade.

What About People Who Cannot Stay on the Medication?

The research does not mean every patient must take a GLP-1 medication indefinitely.

Individual results vary, and some people maintain meaningful weight loss after discontinuing treatment.

Others may benefit from alternative medications, nutrition counseling, structured physical activity, or additional treatment approaches.

Strength training and regular exercise may be especially valuable for preserving muscle mass and helping with weight maintenance.

However, researchers have not yet identified a single reliable strategy to prevent weight regain after stopping GLP-1 therapy.

There is also limited evidence that gradually reducing the dose, rather than stopping, reliably prevents weight regain.

Patients considering discontinuation should discuss the decision with their healthcare provider.

That conversation is particularly important for people taking these medications to manage diabetes or other serious medical conditions, because blood sugar or other health indicators may require closer monitoring when treatment changes.

Medicare’s $50 GLP-1 Program Has an End Date

Affordability is a major concern, particularly for older adults living on fixed incomes.

Medicare introduced the Medicare GLP-1 Bridge on July 1, 2026, to expand access to certain weight-management medications.

Eligible Medicare Part D beneficiaries can obtain covered GLP-1 medications for a $50 monthly copayment.

The program currently includes certain formulations of Wegovy, Zepbound, and Foundayo.

However, eligibility is restricted.

Beneficiaries must meet specific body mass index and health-related requirements, and some people whose GLP-1 medications are already covered through their Part D plans do not qualify.

The Bridge program is temporary and is currently scheduled to end December 31, 2027.

Another Medicare initiative, the BALANCE Model, was intended to provide a longer-term approach to GLP-1 medication access.

The Centers for Medicare & Medicaid Services has postponed its planned 2027 Medicare implementation while it gathers additional data and evaluates the program.

No replacement start date for Medicare participation has been established.

For beneficiaries relying on the Bridge program, that uncertainty makes long-term treatment planning especially important.

The $50 copayment also does not count toward Medicare Part D’s annual out-of-pocket drug spending limit because the Bridge operates outside the regular Part D payment system.

Beneficiaries can review eligibility and coverage information at Medicare.gov/glp1bridge or call 1-800-MEDICARE (1-800-633-4227).

The Larger Lesson About Weight-Loss Medication

The success of GLP-1 medications has changed how doctors approach obesity treatment.

Many patients can achieve substantial weight loss, and clinical trials have documented improvements in important measures of metabolic health.

But the studies examining what happens after treatment ends reveal an equally important lesson.

Weight loss and weight maintenance are not necessarily the same medical challenge.

For many patients, the appetite changes and biological responses that made losing weight difficult in the first place return when medication is withdrawn.

That does not mean everyone will regain the same amount or lose every improvement.

It does mean patients and healthcare providers should discuss long-term treatment plans from the beginning, including what happens if medication becomes too expensive, causes side effects, or is no longer available.

The question isn’t simply how much weight a medication can help someone lose.

It’s how to protect those health improvements over the years that follow.

Front Royal, VA
34°
Sunny
6:57 am4:57 pm EST
Feels like: 34°F
Wind: 1mph S
Humidity: 96%
Pressure: 30.59"Hg
UV index: 0
WedThuFri
68°F / 32°F
72°F / 36°F
72°F / 37°F
Punditry & Prose10 minutes ago

Commentary: Getting Back to Virginia Amid the FAA Chaos Wasn’t ‘The Odyssey,’ But It Certainly Was a Pain

State News19 minutes ago

FAA Ground Stop Disrupts 532 Flights at 4 Virginia Airports

National News27 minutes ago

US Loses Its ‘Measles Elimination Status’ After More Than 25 Years

Interesting Things to Know2 hours ago

Your Boss Sees Your Work. But Does Your Industry Know What You Can Do?

Health2 hours ago

When the Weight Comes Back: What Happens After You Stop Taking GLP-1 Drugs?

Local Government16 hours ago

Gazebo Park Trees Battle a Contagious and Often Fatal Black Mold Infection

Opinion18 hours ago

Virginia Families Are Losing an Opportunity. And for What?

Local News1 day ago

Amazon Pledges Millions to Cover In-Demand Career Training at Virginia Community Colleges

Obituaries1 day ago

Loretta Faye “Cushy” Mullins Roles (1955 – 2026)

Interesting Things to Know1 day ago

Motorized Hiking Gear Gives Walkers an Extra Boost on the Trail

Food1 day ago

From Wine Barrels to Ancient Lakebeds: The Surprising Origins of Everyday Baking Ingredients

Local News2 days ago

Chelsea Academy Lady Knights Capture First State Championship in School History

Obituaries2 days ago

Pattie Lynn Foster Watkins (1973 – 2026)

Home2 days ago

The Dirt Your Guests Notice That You Don’t

Interesting Things to Know2 days ago

Ask Stewart: Tree Stewards Prepare to Celebrate 30 Years of Caring for Our Community

National News2 days ago

States Have 6 More Months to Implement Medicaid Work Requirement, Administration Says

Interesting Things to Know2 days ago

The Dutch Island That Saluted America’s Flag in 1776

Interesting Things to Know2 days ago

Dollywood’s Christmas Schedule Offers Clues to the Busiest Days

Local News3 days ago

Front Royal Winter Shelter Prepares to Open as Social Services Seeks Holiday Help for Local Families

Local News3 days ago

Front Royal Author Brings Irish Folklore to Life with a Talking Dog and a Magical Secret

Historically Speaking3 days ago

Israel: Nation Making

Local News3 days ago

VDOT: Warren County Traffic Alert for Nov. 16 – 20, 2026

Home3 days ago

Thanksgiving Without the Stress: 8 Simple Ways to Enjoy Hosting Your Holiday Dinner

Business3 days ago

Computing Pioneer Found the Secret to Success on a Cross-Country Bicycle Ride

Local Government4 days ago

Initiative, Streamlining, and Industrial Zoning at County Planning Commission Meeting